Bronchenolo® Cough Syrup 150ml
- Brand: PERRIGO ITALIA Srl
- Product Code: 019771043
- Availability: In Stock
- Purchase 3 items for 4.39€ each
- Purchase 4 items for 4.30€ each
- Purchase 5 items for 4.21€ each
Bronchenolo® Cough Syrup - Sedative
It is used to calm coughs.
100 ml of syrup contain: Active ingredient: dextromethorphan hydrobromide 154 mg For excipients, see 6.1
Ethyl alcohol, sodium citrate, citric acid monohydrate, methyl p-hydroxybenzoate, lemon flavor, mint flavor, sucrose, purified water.
In case of hypersensitivity to the components or other closely related substances from a chemical point of view. Children under the age of 6. Patients with respiratory failure or at risk of developing respiratory failure (e.g. patients with chronic obstructive airway disease or pneumonia, patients with ongoing asthma attack or exacerbation of asthma). Patients who are taking or have taken monoamine oxidase inhibitor antidepressants (MAOIs) within the last two weeks.
Adults and children (over 12 years): 3-4 tablespoons (15 ml) per day. One tablespoon every 4-6 hours. Maximum daily dosage: 60 ml. Children from 6 to 12 years: 3-4 half tablespoons (7.5 ml) per day. Half a spoon every 4-6 hours. Maximum daily dosage: 30 ml. After 5-7 days of treatment without appreciable results, the patient should be advised to consult the doctor. DO NOT EXCEED THE RECOMMENDED DOSE
Warnings and Precautions
In the following cases, BRONCHENOL COUGH should only be used after consulting your doctor: - chronic or persistent cough, such as that which occurs in the case of asthma or emphysema, or when the cough is accompanied by excessive secretion - severe hepatic insufficiency - severe renal insufficiency - concomitant use of selective serotonin reuptake inhibitor antidepressants or tricyclic antidepressants (see “Interactions”). Consult your doctor if the cough persists, or if it is accompanied by a high fever, skin rash, or persistent headache. Simultaneous use of other cough and cold products should be avoided. The syrup contains sucrose, this should be taken into account in the case of diabetes or low calorie diets. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. The concomitant use of alcohol should be avoided during therapy with COUGH BRONCHENOL. Do not exceed the maximum recommended dose or frequency of administration. Keep out of the reach and sight of children.
The product should not be used at the same time or within 2 weeks after treatment with monoamine oxidase inhibitor antidepressants (MAOIs), as serious adverse reactions, including serotonin syndrome, have been reported (see “Contraindications”). Patients should consult their physician before taking dextromethorphan in the following situations: Concomitant use of dextromethorphan with selective serotonin reuptake inhibitor antidepressants or tricyclic antidepressants may cause serotonin syndrome with changes in mental status, hypertension, agitation, myoclonus, hyperreflexia, diaphoresis, tremors and tremors (see "Warnings and precautions"); serum levels of dextromethorphan may be increased by concomitant use of cytochrome P450 2D6 inhibitors, such as the antiarrhythmics quinidine and amiodarone, antidepressants such as fluohexitine and paroxetine, or other drugs that inhibit cytochrome P450 2D6 such as haloperidol and thioridazine; the concomitant use of dextromethorphan and alcohol can increase the central nervous system depressant effects of both substances.
Clinical Trial Data The adverse events reported below were observed in clinical studies with dextromethorphan and are considered uncommon adverse reactions (i.e. occurring in ≥1 / 1000 to <1/100 patients). Adverse reactions are listed according to the MedDRA classification. Nervous system disorders: drowsiness; dizziness. Gastrointestinal disorders: gastrointestinal disorders; nausea; He retched; abdominal discomfort. Post-marketing data Adverse reactions identified during post-marketing use of dextromethorphan products are listed below. As these reactions are reported voluntarily from a population of uncertain size, their frequency is unknown but is probably very rare (found in <1/10000 patients). Nervous system disorders: serotonin syndrome. Serotonin syndrome (with altered mental status, agitation, myoclonus, hyperreflexia, diaphoresis, tremors, tremors and hypertension) has been reported with concomitant use of dextromethorphan with antidepressants (monoamine oxidase inhibitors or serotonin reuptake inhibitors) (see "Contraindications" and "Warnings"). Skin and subcutaneous tissue disorders: allergic reactions (e.g. rash, urticaria, angioedema).
Pregnancy and breastfeeding
No data on pregnancy and lactation are available. During pregnancy and lactation, the product should be used only in case of real need and under direct medical supervision.